Clinical studies have been and always will be the foundation to assess the efficacy and safety of new therapies. However, the rise and use of real-world evidence (RWE) can complement clinical studies, and in many cases, provide answers to questions that cannot be addressed by randomized clinical trials (RCTs). In this episode, we explore the topic of real-world data (RWD) and RWE and how this information can be useful for biopharma companies and health authorities in order to help deliver better outcomes for patients and have a positive impact on the overall healthcare system. We also delve into some of the challenges with using this type of data, and we will see how a multi-stakeholder initiative – RWE4Decisions – is tackling those issues.
Our special guests include: Karen Facey from RWE4Decisions, Carlos Martin Saborido from Spanish Ministry of Health and EUCOPE’s Alexander Natz.